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Abstract
AIM
To evaluate the annual cost of patients with Wagner 
grade 3-4-5 diabetic foot ulcer (DFU) from the public 
payer’s perspective in Turkey.
METHODS
This study was conducted focused on a time frame of 
one year from the public payer’s perspective. Cost-of-
illness (COI) methodology, which was developed by the 
World Health Organization, was used in the generation 
of cost data. By following a clinical path with the COI 
method, the main total expenses were reached by 
multiplying the number of uses of each expense item, 
the percentage of cases that used them and unit costs. 
Clinical guidelines and real data specific to Turkey 
were used in the calculation of the direct costs. Monte 
Carlo Simulation was used in the study as a sensitivity 
analysis.
RESULTS
The following were calculated in DFU treatment from 
the public payer’s perspective: The annual average 
per patient outpatient costs $579.5 (4.1%), imaging 
test costs $283.2 (2.0%), laboratory test costs $284.8 
(2.0%), annual average per patient cost of intervention, 
rehabilitation and trainings $2291.7 (16.0%), annual 
average per patient cost of drugs used $2545.8 (17.8%) 
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and annual average per patient cost of medical ma-
terials used in DFU treatment $735.0 (5.1%). The 
average annual per patient cost for hospital admission is 
$7357.4 (51.5%). The average per patient complication 
cost for DFU is $210.3 (1.5%). The average annual per 
patient cost of DFU treatment in Turkey is $14287.70. 
As a result of the sensitivity analysis, the standard 
deviation of the analysis was $5706.60 (n  = 5000, 
mean = $14146.8, 95%CI: $13988.6-$14304.9). 
CONCLUSION
The health expenses per person are $-PPP 1045 in 2014 
in Turkey and the average annual per patient cost for 
DFU is 14-fold of said amount. The total health expense 
in 2014 in Turkey is $-PPP 80.3 billion and the total DFU 
cost has a 3% share in the total annual health expenses 
for Turkey. Hospital costs are the highest component in 
DFU disease costs. In order to prevent DFU, training of 
the patients at risk and raising consciousness in patients 
with diabetes mellitus (DM) will provide benefits in 
terms of economy. Appropriate and efficient treatment 
of DM is a health intervention that can prevent com-
plications. 
Key words: Diabetic foot; Diabetes complications; Cost 
of illness; Burden of illness; Amputation
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Core tip: The purpose of this study is to evaluate 
the annual cost of patients with Wagner grade 3-4-5 
diabetic foot ulcer (DFU) in Turkey. Cost-of-illness 
methodology was used in the generation of cost data. 
Monte Carlo Simulation was used in the study as a 
sensitivity analysis. The average annual per patient cost 
of DFU treatment in Turkey is $14287.70. As a result 
of the sensitivity analysis, the standard deviation of the 
analysis was $5706.60 (n  = 5000, mean = $14146.8, 
95%CI: $13988.6-$14304.9). Hospital costs are the 
highest component in DFU disease costs. 
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INTRODUCTION
Diabetes mellitus (DM) is a health problem, the severity 
of which is gradually increasing all over the world. DM 
exists in approximately 8.3% of the world’s population. 
In 2013, 10.8% ($548 billion) of global health expenses 
were for DM and its complications[1]. DM amounts to 
23% (approximately 10 billion Turkish liras - TL) of the 
total health expenses of Turkey in 2012[2]. 
Diabetic foot ulcer (DFU) is a frequently observed, 
serious, and chronic complication of DM. The risk of occ-
urrence during diagnosis can be up to 25%, and 2% of 
cases require amputation[3]. Half of the cases of non-
traumatic foot amputation are due to DM[4]. It is estimated 
that a patient’s foot is amputated due to DFU once every 
30 s worldwide. The rate of recurring amputation is 
between 30% and 50% in the following three years in 
the patients who are amputated once. The rate of death 
within five years following amputation is 50%[5].
Approximately 400000 DFU cases are observed in 
Turkey, and 7700 amputation procedures are performed 
annually due to DFU[6]. As the prognosis of cases after 
amputation is considered, the importance of rational 
treatment in DFU becomes significant. Surgical and non-
surgical basic wound care principles are essential in the 
efficient recovery of the wounds. Prevention of ulcers and 
fighting against wound site infections that are difficult to 
heal are as important as its treatment. DFU treatment 
requires multidisciplinary treatment procedures. DFU 
has direct costs as well as indirect costs and it is very 
important to try to increase quality of life of the patients 
during treatment, minimize the disease costs, and ad-
minister correct treatment that enables the person to 
remain as a productive and value-adding individual as 
well as to prevent occurrence of the disease. 
The purpose of this study is to evaluate the annual 
cost of patients with Wagner grade 3-4-5 DFU from the 
public payer’s perspective in Turkey.
MATERIALS AND METHODS
This study was conducted focused on a time frame of 1 
year from the perspective of the Turkish reimbursement 
institution. Cost-of-illness (COI) methodology, which was 
developed by World Health Organization, was used in the 
generation of cost data[7]. 
COI methodology
Cost is a monetary measure for the sacrifices made for 
achieving a certain goal. Cost is the value of a source. 
Economists use the concepts of “opportunity cost” or 
“monetary cost” in COI studies. Even though no money 
is spent, it is always considered that scarce resources that 
can be used in other areas are used. The basic idea behind 
cost estimation is that once a health service is provided to 
a person, the resources that are used will not be available 
anymore for other people or alternative social uses. 
COI studies are used by policymakers for budget justi-
fication, determining the priorities in financing biomedical 
research, and development of intervention programs for 
preventing and treating diseases[8,9].
Cost studies can be based on either prevalence or 
incidence, depending on the purpose of the analysis. The 
approach based on prevalence is more frequently used. 
In the approach based on prevalence, the total costs are 
calculated for a patient population in a certain area in a 
certain period of time[8,9]. The period of time is usually 1 
year. Said studies are required for health policymakers 
for budget planning and decisions[8]. Studies based on 
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incidence calculate the lifetime cost of a patient who 
has a disease, starting from diagnosis to treatment, 
or if it is a chronic disease, until death[8,9]. The analysis 
perspective determines which resources will be used in 
the calculation[8]. Perspective shows who is affected as 
the resource allocation preference is made and in whose 
name the decisions are made[10,11]. COI analyses can be 
performed with different perspectives, such as societal 
perspective, patient perspective, or perspective of the 
third person/public payer[8]. 
Health economy research defines the costs in two 
main categories. The first one is the medical costs that 
occur due to disease, and the second one is the other 
disease-associated costs including non-medical costs 
that occur due to disease[9-12]. There are direct and 
indirect costs in each category. Direct costs refer to which 
payments are made and indirect costs refer to which 
resources are lost[9]. The direct medical costs include all 
types of exclusive and non-exclusive uses of resources 
(not only monetary expenditures) such as costs related 
to hospital services, outpatient services, laboratory tests, 
supplies, prescriptions, physical therapy, care services 
at home and care centers, caregiver costs, and services 
such as ambulance, etcetera, and the use of health 
personnel and departments of hospitals. In addition, they 
include the future costs or savings such as costs of other 
tests with false positive or true positive results during 
monitoring associated with said disease and hospital 
admissions and treatment costs. Direct medical costs 
are calculated by classification according to the types of 
payments and expenses[10]. Indirect costs are the costs 
of morbidity and mortality[9].
Assessment and evaluation
By following a clinical path with the COI methodology, 
the main total expenses were reached by multiplying the 
number of uses of each expense item, the percentage of 
cases that used them, and unit costs. The direct medical 
costs, which are the outpatient, laboratory and imaging 
methods, prescribed drugs, medical supplies that are 
directly used during the course of treatment of disease, 
and the amount spent for the hospital admissions and 
interventions, were calculated, and non-medical direct 
expenses were ignored, as there were no sufficient data for 
Turkey. The intangible costs including pain, unhappiness, 
distress, misery, stress, et cetera, caused by the disease 
in the individual were also not taken into consideration in 
this study. The indirect costs including the societal costs 
caused by the disease, disabilities, or premature deaths 
were also excluded from the study.
The clinical guidelines were followed in calculating the 
direct costs and actual data were used for some cases. 
The cost of disease was calculated by rating the 
Wagner classification that shows the grade of foot 
ulcer[13]. The Wagner classification rates of patients with 
DFU in Turkey were as follows: Grade 1: 7.7%, grade 
2: 27.2%, grade 3: 35.2%, grade 4: 25.4%, and grade 
5: 4.5%[14-16]. The costs of patients of grades 3-4-5 
according to the Wagner classification were calculated. 
The Medical Enforcement Declaration (MED), which 
is officially declared by the institution, is used for the 
payment of health services by the reimbursement in-
stitution in Turkey[17]. The costs for all medical services 
used in the calculations were obtained from MED. The 
drug expenses were based on the 2015 list of the 
Republic of Turkey Ministry of Health Turkish Medicines 
and Medical Devices Agency. The drugs were classified 
according to the active ingredients and all forms of all 
products included in the reimbursement list related to the 
active ingredients and were included in the analysis, and 
their average values were reflected to the calculations. 
Public discounts, current public paid costs, and costs 
related to medical materials such as all orthosis and 
prosthesis devices were obtained from MED. The costs 
were calculated according to United States dollars by 
using the foreign exchange rate in 2014 ($1.00 = 1.179 TL). 
The average institution cost was calculated as the 
admission fee for treatments administered in an out-
patient clinic. The health organizations, clinical branches, 
and surgical branches that can administer DFU treat-
ment were chosen, the prices of related outpatient were 
obtained from MED, and the average values were calcu-
lated. The average costs of pricing per admission of the 
patients with DFU to the outpatient clinic were included 
in the analysis according to said average value calculated 
for each branch. The cost for outpatient to which the 
patients were transferred for consultation was 10.12 
procedure points in accordance with MED. Some of the 
medical materials used in payment per admission to the 
outpatient clinic were included in the admission fee. The 
examinations that were not included in the outpatient 
clinic admission fee were included in the costs according 
to MED. 
Monte Carlo Simulation (MCS) was used in the study 
as the sensitivity analysis. MCS is a technique that uses 
random numbers and a trial-and-error method without 
using any formula. MCS provides an estimate for the 
statistical distribution of the possible costs. At the same 
time, the distribution of variables that constitute the 
costs is obtained. Simulation technique is a methodology 
employed to solve problems, not a theory. Approach 
of this technique to the problems varies depending 
on system structure and the model to be constructed 
based on this structure. During the simulation process, 
a sample is generated by the distribution of the variance 
observed in the proper distribution forms. Random 
values are used for uncertain variables. MCS can assign 
random values to all variables and parameters in accor-
dance with the probabilities. The simulation is based 
on the random number generation. For example, for a 
possibility of 66 that requires osteomyelitis treatment, 
probability distribution according to the random numbers 
drawn from a normal distribution is as follows: The 
patient will receive the osteomyelitis treatment if the 
random number drawn is between 00 and 66, and for 
the numbers drawn between 67 and 99, the patient will 
be treated without a need for osteomyelitis treatment. In 
this study, distribution parameters were calculated at the 
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rates of diagnosis-treatment and follow-up steps for DFU. 
In this analysis, the distribution values were provided 
with the results obtained by performing 5000 simulations 
for each possible situation. The time horizon is 1 calendar 
year. 
RESULTS
The outpatient clinics visited and complications ex-
perienced by the patients according to proportional 
distribution vary during the treatment for DFU, and this 
creates different cost items in admissions made to the 
outpatient clinic[14,18-27]. According to the public payer’s 
perspective, the average annual per patient outpatient 
cost was $579.5 in DFU treatment (Table 1).
The distribution of imaging tests and laboratory tests 
that are required to be performed during the treatment 
of DFU was obtained from the literature. While bone 
curettage culture and bone biopsy were required in 66% 
of the patients[14,18,25-27] scintigraphy is performed in 
Wagner grade 4 and 5 gangrene patients (20.6%)[15,16]. 
Some of the laboratory tests and imaging procedures 
performed for the patients with DFU are included in the 
payment per admission made to the outpatient clinic. 
The items that are not included in the payment per 
admission were added to the calculations according to 
the MED list. Culture, gram staining, and antibiogram 
analyses must be performed in patients with DFU. In 
DFU treatment, the average annual per patient cost for 
imaging tests was $283.2, and laboratory test cost was 
$284.8 (Table 2).
Wagner 3-4-5 DFU patient groups (44.9%) are admitted 
to inpatient for an average of 23 d a year[18,19,21,23,26,27]. 
The average rate of amputation in said patients is 
53.9%[14,18,19,22-24,26,27]. The average hospitalization period 
for the patients who are amputated is 42 d[23]. Six 
percent of patients are hospitalized for five days due to 
revascularization surgery, and the patients who have 
graft/flap (24%) are hospitalized for an average of 12 d 
(Table 3)[28,29]. 
The average annual per patient cost of inpatient care 
due to DFU was $7357.4.
All of the patients received training on a diabetic 
foot. The average rate of patients receiving treatment 
for osteomyelitis is 66%[14,18,25-27]. Wound debridement 
is performed in patients at an average of 10.1%. The 
average rate of patients who had graft/flap was 24%. 
Revascularization surgery is performed in two ways: 
Percutaneous transluminal angioplasty (6%) or bypass 
(6%)[18-20,26]. An average of 8.0% of the patients receives 
hyperbaric oxygen treatment[18] over an average of 40 
sessions[20,24]. The rate of patients receiving physical 
therapy and rehabilitation is 16.6% (30.8% of the 
amputated patients) (Table 4)[18,19,22,25,27].
The average annual per patient cost of intervention, 
rehabilitation, and training for DFU was $2291.7.
Antibiotic treatment of DFU can be grouped into 
three categories: Low risk, high risk, and serious risk. In 
wounds with low risk (24%), clindamycin (4 × 300 mg) 
or cephalexin (4 × 500 mg) is used for 14 d. In wounds 
with high risk (60.3%), the patients are admitted to the 
hospital and one of the following parenteral treatments is 
administered for 14 d: Piperacillin/tazobactam, ampicillin 
sulbactam, cephalexin, third generation cephalosporin + 
clindamycin, or ciprofloxacin + clindamycin. The patients 
with wounds with serious risk (15.3%) must be admitted 
to the hospital and one of the following treatments 
is administered for 14-21 d (for 6 wk if osteomyelitis 
exists): Ampicillin + gentamicin + clindamycin, imipenem/
meropenem, vancomycin, piperacillin/clavulanate, or 
ticarcillin/clavulanate[30,31]. 
Average unit cost
($-PPP 2014)
Outpatient clinics
   Endocrinology and metabolic diseases 27.1
   Orthopedics and traumatology 25.4
   Plastic and reconstructive surgery 26.8
   Dermatology 22.4
   Infectious diseases 27.3
   Neurology 27.5
   Nephrology 27.4
   Cardiovascular surgery 27.8
   Physical therapy and rehabilitation 26.4
   Algology 31.0
   Medical ecology and hydroclimatology 25.6
Consultations 
   Infectious diseases - consultation   5.2
   Orthopedics and traumatology - consultation 
   Cardiovascular surgery - consultation 
   Plastic and reconstructive surgery - consultation 
   Dermatology - consultation 
Table 1  The average unit cost of outpatient to which the 
admissions are made in the treatment of diabetic foot ulcer
Name of test Average unit cost ($-PPP 2014)
Imaging tests
   Direct foot X-ray Included in outpatient clinic 
admission fee   Electrocardiogram 
   Unilateral chest X-ray 
   Doppler ultrasonography   32.4
   Magnetic resonance angiography   55.1
   Angiography 392.3
   Scintigraphy 131.7
Laboratory tests
   Bone biopsy   97.6
   Tissue culture   97.6
   Aspiration/swab culture   33.8
   Bone curettage culture   97.6
   HbA1c     3.4
   Bleeding profile (Pre-op)   12.2
   Glucose Included in outpatient clinic 
admission fee   Hemogram 
   C-reactive protein 
   Red blood cell sedimentation rate
   Albumin 
   Kidney function tests 
   Liver function tests 
   Hepatitis markers 
Table 2  Unit costs of imaging - laboratory tests used in the 
treatment of diabetic foot ulcer
HbA1c: Hemoglobin A1c. 
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Insulin is used in all of the patients. Furthermore, 
the cost of anti-thrombotic treatment was added to the 
calculation for 85% of the patients.
The average annual per patient cost of medication 
used in the treatment of DFU was $2545.8.
A total of 42.6% of the patients (non-ischemic 
wounds) use wound sheath as a medical supply[18,20,26,27]. 
For 53.9% of the patients, the costs of orthosis-pro-
sthesis devices were reflected in the calculation by 
considering the average values for the supplies and their 
weighted use (Table 5).
The average annual per patient cost of medical 
supplies used in the treatment of DFU was $735.0.
Some complications of methods applied in the treat-
ment of DFU can be observed as well. During treatment 
of DFU, infection can be observed after amputation 
in 12.8% of the patients and re-amputation can be 
observed in 11.5% of the patients[16]. Complications 
such as barotraumatic otitis (10.26%) and hypoglycemia 
(0.85%) can be observed in patients treated with 
hyperbaric oxygen treatment[20]. The average cost of 
complications per patient with DFU was $210.3.
The average annual per patient cost of DFU treatment 
in our country was $14287.7 (Table 6).
Sensitivity analysis
DFU includes use of some interventional procedures 
and pharmacological agents as well as various services 
provided by outpatient, inpatient, and laboratory units 
during diagnosis and treatment stages and also includes 
the cost of side effects of said procedures. Separate 
calculations were made for each variable for the dis-
tribution and accuracy of the results. Thus, the results 
of each variable are represented by the probabilities 
calculated within. As a result of the sensitivity analysis 
(Table 7), the standard deviation of the analysis was 
$5706.6 (n = 5000; mean = $14146.8, 95%CI: 
$13988.6-$14304.9).  
The health expenses per person are $-PPP 1045 
in 2014 in Turkey and the average annual per patient 
cost for DFU is 14-fold of said amount. The total health 
expense in 2014 in Turkey is $-PPP 80.3 billion and the 
total DFU cost has a 3% share in the total annual health 
expenses for Turkey.
DISCUSSION
In this study, the direct medical costs of DFU were in-
vestigated from the public payer’s perspective in Turkey. 
In similar studies conducted on a limited number of 
patients and in a single center, the estimated treatment 
costs of DFU patients were investigated in Turkey. In 
a retrospective study conducted by Keskek et al[21] in 
2010 on patients with type 2 diabetes mellitus (T2DM) in 
Turkey, it was demonstrated that the costs of treatment 
in the hospital per patient in patients with DFU in a 
tertiary hospital were higher than those of the patients 
with T2DM without any chronic complications. The cost 
of one hospitalization for each patient was calculated in 
the study conducted by Keskek et al[21]. The cost of the 
hospital per admission in patients with DFU was $976.10. 
The cost of supplies was calculated at 42.6%, and 57.4% 
was calculated as cost of service. In the cost study 
related to DM and chronic complications conducted with 
7095 patients in 2009 in Turkey, the direct costs of DFU 
Admission to department Rate of 
patients (%)
Hospitalization 
period
Wound follow-up 44.9 23
Amputation surgery 53.9 42
Revascularization surgery 12.0   5
Plastic and reconstructive surgery - 
graft/flap
24.0 12
Table 3  Hospitalizations in departments for treatment of 
diabetic foot ulcer
Interventions Rate of 
patients (%)
Average cost
($-PPP 2014)
Osteomyelitis treatment   66.0   605.0
Wound debridement   10.1   813.7
Graft/flap   24.0   602.1
Percutaneous transluminal angioplasty     6.0 6250.9
Bypass     6.0 6512.4
Amputation   53.9   961.7
Hyperbaric oxygen treatment     8.0      70.01
Physical therapy and rehabilitation   16.6      31.31
Diabetic foot patient training 100.0        1.5
Table 4  Medical and surgical interventions performed in the 
treatment of diabetic foot ulcer and their costs
1Cost per session.
Drugs and medical materials Average cost
($-PPP 2014)
Insulin 1118.9
Antibiotics - in the group of wounds with low risk     78.1
Antibiotics - in the group of wounds with moderate risk   240.0
Antibiotics - in the group of wounds with serious risk   764.5
Anti-thrombotic 1348.4
Orthosis and prosthesis devices   961.5
Wound sheath   101.8
Table 5  Distributions of annual drug use of patients regarding 
drugs and other medical materials
Cost components Average per patient annual cost ($-PPP)
Outpatient costs     579.5
Laboratory costs     284.8
Imaging test costs     283.2
Inpatient costs   7357.4
Intervention costs   2291.7
Drug costs   2545.8
Medical material costs     735.0
Complication costs     210.3
Total cost per patient 14287.7
Table 6  The average annual cost per patient in diabetic foot 
treatment ($-PPP 2014)
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were TL 1545, and in cases of amputation, the annual 
cost was TL 2386. In said study, the prevalence of DFU 
was 9.0% and its incidence was 2.0% in patients with 
DM, and the incidence of amputation was 0.2% and its 
prevalence was 1.0% in patients with DM[32]. 
The costs of treatment vary according to the dis-
tribution of outpatient clinics visited by DFU patients, 
medication and medical materials used in treatment, 
laboratory and imaging tests performed, and the need 
for admission to a hospital and surgical intervention. 
The period of hospitalization is an important factor 
that causes high costs. The period of hospitalization is 
prolonged due to uncontrolled hyperglycemia, long-
term wound care, infections, debridement, amputation, 
and newly occurring complications; therefore, the cost 
of treatment increases. In our study, the average direct 
total cost of DFU treatment per patient in our country is 
$14287.7. Hospital admissions are $7357.4 (51.5%) of 
said cost. 
In the studies conducted based on prevalence from 
the perspective of the health care payer, the cost of DFU 
in the United States was between $1892 and $48354[33-36]. 
In the study conducted by Harrington et al[33], calculations 
were made using the insurance database of 1995 in the 
United States. The cost of DFU was $15309. Inpatient 
costs are 74% of the total cost[33]. The study conducted 
by Stockl et al[34] was performed by using the insurance 
database of 2000 and 2001. The cost per episode 
increases according to the severity of DFU. While the cost 
of grade 1 was $1892 per episode, the cost of grade 4/5 
was $27721 per episode. Inpatient costs amount to 77% 
of the total cost[34]. In the study conducted by Sargen et 
al[35], the cost of DFU was studied using the insurance 
database of calendar year 2007. In said study, the cost 
of DFU was $31363, and if amputation was performed, 
said cost was $48354[35]. In the study conducted by 
Margolis et al[36] based on the Medicare database of the 
United States, the amounts of reimbursement payments 
made for DFU and lower extremity amputations between 
2006 and 2008 were calculated. The cost per patient in 
patients with DM with DFU was $31600 for 2006, $33100 
for 2007, and $35100 for 2008. The cost per patient in 
patients with DM who had a lower extremity amputation 
was $49300, $51200, and $54100, respectively[36].
Kerr et al[37] calculated the cost of DFU for the 
National Health Service (NHS) in England in 2010-2011. 
Outpatient care, inpatient care, and post-amputation 
care were calculated in the study conducted by Kerr 
et al[37]. Moreover, calculations for materials such as 
wheelchairs, et cetera, were performed as well. In the 
study, it was found that 0.6% of the expenditures of NHS 
consisted of DFU for 2010-2011. Half of the total cost 
consisted of primary and community care of DFU. Some 
8.8% of the total hospital costs associated with diabetes 
were spent for DFU. The existence of DFU increases the 
period of hospitalization of the patients by 2.51-fold. The 
outpatient cost was £4994. The inpatient cost was £3620 
per admission. The post-amputation care cost was £2879 
per patient.
In the study conducted by Girod et al[38] in 2003 in 
France, the monthly cost of DFU was €697 for outpatient 
care and €1556 for hospital care. While 70% of the total 
cost consisted of hospital costs in the patients admitted 
to the hospital, the percentage of drug costs was 10%[38]. 
Prompers et al[39] prospectively calculated the societal 
disease cost for DFU in Europe in 2003-2004 with the 
approach based on incidence. In the study, in which 14 
sites from 10 European countries were included, the 
direct cost of DFU per patient was €9446 and the cost 
per patient in amputated patients was €24540. The 
indirect cost of DFU was €645 per patient and said cost 
was €681 in the amputated patients. Hospital costs were 
39% of the total cost of DFU[39]. 
In the study conducted by Rezende et al[40] in 2008 in 
Brazil with a simulated hypothetical cohort, approximately 
30% of patients with DFU were admitted to the hospital. 
It was stated that extremity amputation was performed 
in 14% of patients with DFU. The total annual cost 
of patients admitted to the hospital due to DFU was 
approximately $264 million ($51 million-461 million) and 
said cost was $128 million ($24.5 million-$222.3 million) 
for the amputated patients[40].
In a study conducted in Pakistan in 2005 for inve-
stigating the direct cost of DFU treatment in a tertiary 
hospital, it was demonstrated that the cost of treatment 
increases as DFU progresses. The cost for University 
of Texas Classification grade 1 phase B was £21 and 
the same cost was £288 for grade 2 phase D and £378 
for grade 3 phase D. In the study, in which 62% of the 
patients had a grade 2 ulcer, the average cost was £376 
for major amputations and £389 for minor amputations. 
The average annual health expense per patient was £1.7 
Cost components $-PPP (n  = 5000)
Average SD 95%CI Median 
Outpatient costs     576.2   196.1 568.0-584.4     565.5
Cost of imaging tests     279.4   205.6 267.9-291.0     219.2
Laboratory costs     283.3     64.7 278.7-287.7     254.8
Inpatient costs   7290.3 5047.9 6864.8-7715.8   8969.5
Intervention costs   2212.3 2347.7 1980.3-2444.4   1568.2
Drug costs   2554.4   566.3 2490.7-2618.2   2707.4
Cost of medical supplies     742.0   538.0 673.9-810.2     961.5
Cost of complications     208.7   452.7 145.0-272.5         0.0
Total cost 14146.8 5706.6 13988.6-14304.9 14615.4
Table 7  Result of sensitivity analysis for the total costs of diabetic foot ulcer
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in Pakistan for the period the study was conducted[41].
In a study comparing the costs of United States 
Medicare and private insurance patients in 2013, it was 
calculated that the annual treatment cost of DFU was 
$11296 for Medicare ($27040 vs $15743) and $15329 
for privately insured ($25931 vs $10602) patients[42].
In conclusion, despite the fact that it is difficult to 
compare the costs between countries due to the social 
and economic differences in terms of methods used in 
the treatment of DFU, said disease is a complication 
that decreases the quality of life of the patient, is life 
threatening, and significantly increases the socioe-
conomic costs of DM. 
The annual cost of DFU in Turkey was found to be 
similar to the results of cost studies conducted based on 
prevalence for the other countries. 
DM-related complications are severe and will often 
require hospitalization for long periods. In some cases, 
it exposes a necessity for major surgery. The highest 
cost component was the hospital cost in the COI for 
DFU. Improvements in inpatient durations and health 
interventions will reduce the costs of related disease. 
The second leading cost component was found to be 
the pharmacy costs. Among these costs, antithrombotic 
drugs have the largest share. Increased use of generic 
anti-thrombotic drugs may be a powerful factor for re-
ducing this cost.
The most effective way of reducing the costs related 
to DFU is the prevention of the complication itself. 
Another alternative is delaying the complication as long 
as possible. In order to prevent DFU, it will be helpful 
to provide training to the patients at risk and to raise 
awareness in patients with DM in terms of economy. 
Appropriate and efficient treatment of DM is a health 
intervention that can prevent complications. Further 
studies may help in discovering more effective healthcare 
strategies and improving the healthcare quality.
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